Vir Biotechnology Appoints Timothy Coughlin to Board of Directors and Audit Committee Leadership Role
Vir Biotechnology has announced the appointment of Timothy Coughlin to its Board of Directors, effective June 9, 2026. In addition to joining the board, Coughlin will serve as Chair of the company’s Audit Committee, bringing decades of financial, operational, and strategic leadership experience to the biotechnology company as it advances a growing pipeline of innovative therapies.
The appointment comes at an important stage in Vir Biotechnology’s evolution as the company works to expand its clinical portfolio and progress multiple development programs across infectious diseases and oncology. Company leadership believes Coughlin’s extensive experience guiding biotechnology organizations through periods of growth, commercialization, and strategic transformation will provide valuable support as Vir advances its long-term objectives.
Strengthening Governance During a Critical Growth Phase
Vir Biotechnology has spent recent years building a diversified portfolio focused on addressing serious diseases with significant unmet medical needs. As the company moves closer to key clinical and regulatory milestones, strengthening corporate governance and financial oversight has become increasingly important.
The addition of Timothy Coughlin to the Board of Directors reflects Vir’s commitment to ensuring that experienced industry leaders help guide the organization through its next phase of development.
Marianne De Backer, Chief Executive Officer of Vir Biotechnology, described the appointment as a significant addition to the company’s leadership structure. She noted that Coughlin’s combination of financial expertise, operational insight, and strategic discipline has played an important role in helping organizations evolve from development-stage enterprises into fully integrated commercial businesses.
According to De Backer, his broad experience spanning drug discovery, clinical development, commercialization, and corporate governance will be highly beneficial as Vir continues to advance its scientific programs and translate innovative research into therapies for patients.
The company expects Coughlin’s perspective to contribute to both strategic decision-making and financial stewardship as it pursues growth opportunities and advances its pipeline.
Supporting the Development of Innovative Therapies
Vir Biotechnology’s current development strategy focuses on several areas of high unmet medical need, including chronic viral infections and cancer.
Among the company’s most closely watched programs is its potential best-in-class treatment regimen for hepatitis delta, a serious liver disease caused by infection with the hepatitis delta virus. Hepatitis delta remains one of the most severe forms of viral hepatitis and can lead to accelerated liver damage, cirrhosis, and liver failure.
The company is also investing heavily in oncology research through its masked T-cell engager platform. These investigational therapies are designed to target solid tumors while potentially improving safety and efficacy compared with earlier generations of immune-based cancer treatments.
Commenting on his appointment, Coughlin expressed enthusiasm about joining Vir at a time when several promising programs are advancing through development.
He highlighted the company’s efforts to develop innovative treatments for hepatitis delta and noted the potential of its oncology pipeline, particularly its portfolio of masked T-cell engagers targeting solid tumors.
Coughlin emphasized that Vir is positioned to make a meaningful impact on patients facing serious diseases and stated that he looks forward to supporting the company’s mission and strategic goals as a member of the Board of Directors.
Extensive Experience in Biotechnology Leadership
Coughlin brings a wealth of experience from leadership positions across the biotechnology, pharmaceutical, healthcare, and financial sectors.
He is perhaps best known for his tenure as Chief Financial Officer of Neurocrine Biosciences, where he played a central role in one of the biotechnology industry’s notable transformation stories.
During his time at Neurocrine, the company evolved from a clinical-stage biotechnology organization into a fully integrated commercial pharmaceutical enterprise. This transition required navigating numerous challenges, including product development risks, regulatory hurdles, financing requirements, and commercial execution.
Coughlin helped guide the company through periods of uncertainty while supporting efforts to advance important therapies to market. Under Neurocrine’s leadership team, the company successfully rebuilt momentum following a significant regulatory setback and ultimately launched products that delivered value to both patients and shareholders.
His experience managing corporate growth during periods of rapid expansion is expected to be particularly relevant as Vir Biotechnology seeks to advance multiple late-stage and emerging clinical programs.
Deep Financial and Operational Expertise
Prior to joining Neurocrine Biosciences, Coughlin held leadership roles within the healthcare delivery sector.
He served as Vice President of Financial Services at Catholic Health Initiatives, one of the nation’s largest integrated healthcare systems. In this position, he gained experience overseeing complex financial operations within a large healthcare organization.
Earlier in his career, he worked in the Health Sciences practice at Ernst & Young, where he served as a Senior Manager. His responsibilities included advising healthcare and life sciences organizations on financial management, accounting, compliance, and operational issues.
This combination of biotechnology, healthcare, and financial services experience provides Coughlin with a broad perspective on the challenges and opportunities facing life sciences companies throughout their development lifecycle.
His expertise in financial oversight and risk management aligns closely with the responsibilities associated with leading Vir Biotechnology’s Audit Committee.
Significant Boardroom Experience
In addition to his executive leadership background, Coughlin has accumulated substantial experience serving on corporate boards.
He currently serves as Chair of the Board of Directors at aTyr Pharma, where he helps oversee strategic planning, governance, and corporate development activities.
He is also a member of the Board of Directors at ADC Therapeutics and Travere Therapeutics, both companies focused on developing therapies for serious diseases.
Over the course of his career, he has contributed to board-level decision-making across multiple stages of corporate growth, from emerging biotechnology companies to commercial-stage organizations.
His previous board service includes positions at Fate Therapeutics and Peloton Therapeutics. Peloton Therapeutics was acquired by Merck & Co. in 2019 in a transaction that highlighted the value of innovative oncology assets within the biotechnology sector.
This extensive governance experience is expected to strengthen Vir’s board as the company evaluates strategic opportunities, pipeline investments, and long-term growth initiatives.
Strong Educational Foundation
Coughlin’s professional accomplishments are supported by a strong academic background in both finance and international business.
He earned a bachelor’s degree in accounting from Temple University and later completed a master’s degree in international business at San Diego State University.
In addition, he is a Certified Public Accountant (CPA) in both California and Pennsylvania, reflecting his extensive expertise in financial reporting, auditing, and corporate governance.
These qualifications have helped shape a career focused on financial leadership, operational excellence, and strategic growth within highly regulated industries.
Positioning Vir Biotechnology for the Future
The appointment of Timothy Coughlin comes as Vir Biotechnology continues to pursue its mission of developing transformative treatments for patients affected by serious infectious diseases and cancer.
As the company advances clinical programs targeting hepatitis delta and expands its oncology pipeline, experienced leadership and strong governance will play an increasingly important role in supporting execution and long-term value creation.
By adding a seasoned biotechnology executive with proven experience in commercialization, corporate finance, and board governance, Vir Biotechnology is strengthening its leadership foundation during a period of significant opportunity.
With a track record of helping biotechnology companies navigate complex transitions and achieve sustainable growth, Coughlin is expected to contribute meaningfully to Vir’s strategic direction as the company works to bring innovative therapies to patients around the world.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
